SG10201606635SA - Virus like particle composition - Google Patents

Virus like particle composition

Info

Publication number
SG10201606635SA
SG10201606635SA SG10201606635SA SG10201606635SA SG10201606635SA SG 10201606635S A SG10201606635S A SG 10201606635SA SG 10201606635S A SG10201606635S A SG 10201606635SA SG 10201606635S A SG10201606635S A SG 10201606635SA SG 10201606635S A SG10201606635S A SG 10201606635SA
Authority
SG
Singapore
Prior art keywords
virus
particle composition
particle
composition
Prior art date
Application number
SG10201606635SA
Other languages
English (en)
Inventor
Ryuji Ueno
Wataru Akahata
Original Assignee
Vlp Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48984367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201606635S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlp Therapeutics Llc filed Critical Vlp Therapeutics Llc
Publication of SG10201606635SA publication Critical patent/SG10201606635SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • C07K14/1808Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201606635SA 2012-02-16 2013-02-15 Virus like particle composition SG10201606635SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261599746P 2012-02-16 2012-02-16

Publications (1)

Publication Number Publication Date
SG10201606635SA true SG10201606635SA (en) 2016-10-28

Family

ID=48984367

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201404711WA SG11201404711WA (en) 2012-02-16 2013-02-15 Virus like particle composition
SG10201606635SA SG10201606635SA (en) 2012-02-16 2013-02-15 Virus like particle composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201404711WA SG11201404711WA (en) 2012-02-16 2013-02-15 Virus like particle composition

Country Status (17)

Country Link
US (2) US9249191B2 (zh)
EP (1) EP2814847B1 (zh)
JP (2) JP6306518B2 (zh)
KR (1) KR102181258B1 (zh)
CN (2) CN113248626A (zh)
AP (1) AP2014007864A0 (zh)
AR (1) AR092796A1 (zh)
AU (1) AU2013221187B9 (zh)
BR (1) BR112014020052B8 (zh)
CA (1) CA2863695C (zh)
MX (1) MX357202B (zh)
NZ (2) NZ628206A (zh)
RU (1) RU2705301C2 (zh)
SG (2) SG11201404711WA (zh)
TW (1) TWI695844B (zh)
WO (1) WO2013122262A1 (zh)
ZA (1) ZA201405694B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628206A (en) 2012-02-16 2016-03-31 Vlp Therapeutics Llc Virus like particle composition
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP6734651B2 (ja) * 2013-06-03 2020-08-05 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC マラリアワクチン
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
KR102532832B1 (ko) 2014-09-11 2023-05-16 브이엘피 테라퓨틱스 인코포레이티드 플라비바이러스 바이러스 유사 입자
GB2535753A (en) * 2015-02-26 2016-08-31 The Native Antigen Company Particles comprising fusion proteins
US10166281B2 (en) * 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
CN105176936B (zh) * 2015-10-23 2019-01-11 中国科学院武汉物理与数学研究所 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用
CA3009799A1 (en) * 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particles encapsulating fusion proteins containing linked epitopes
KR101875055B1 (ko) * 2016-10-19 2018-07-06 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
CN111818943A (zh) 2018-01-04 2020-10-23 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
AU2019216873A1 (en) * 2018-02-07 2020-08-20 Imugene Limited A vaccine composition and uses thereof
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
CN112852852B (zh) * 2019-11-27 2023-07-25 中国医学科学院医学生物学研究所 一种ox40抗原表位重组病毒样颗粒及其制备方法和应用
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
SG48390A1 (en) 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
US5580773A (en) * 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
AU3289199A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Antigen library immunization
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド Pd−1、b7−4の受容体、およびその使用
US20110262389A1 (en) * 2001-02-13 2011-10-27 Mosca Joseph D Tumor-derived Biological Antigen Presenting Particles
WO2002096939A2 (en) 2001-05-30 2002-12-05 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
US20050031592A1 (en) 2002-11-13 2005-02-10 Doolan Denise L. Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines
US7790181B2 (en) 2003-05-29 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Live attenuated viral vaccines for Eastern Equine Encephalitis virus
BRPI0411099A (pt) * 2003-06-05 2006-07-18 Wyeth Corp composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
CN101151272A (zh) 2003-12-01 2008-03-26 陶氏环球技术公司 在假单胞菌中生产重组二十面体病毒样颗粒
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
JP5108521B2 (ja) 2004-10-14 2012-12-26 クルセル ホランド ベー ヴェー マラリア初回免疫/追加免疫ワクチン
JP4819792B2 (ja) 2005-02-16 2011-11-24 国立大学法人東京工業大学 改変されたウイルスカプシドタンパク質及びその使用
CA2981431C (en) 2005-06-08 2021-04-13 Dana-Farber Cancer Institute Inc. Use of compounds that reduce activity or expression of programmed cell death-1 to treat lymphoma
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
JP5093097B2 (ja) 2006-03-03 2012-12-05 小野薬品工業株式会社 細胞表面機能分子の細胞外領域多量体
WO2008025067A1 (en) 2006-08-30 2008-03-06 Hepgenics Pty Ltd Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
US9234181B2 (en) 2007-11-26 2016-01-12 Novartis Ag RNA expression cassette and cells for making alphavirus particles
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
RU2571223C2 (ru) 2009-09-18 2015-12-20 Фронхофер Юэсэй Инк. Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
US9487563B2 (en) * 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
AU2012269907B2 (en) 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
CN102321639B (zh) * 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
SG11201401733VA (en) 2011-10-25 2014-09-26 Florida Gulf Coast University Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
NZ628206A (en) * 2012-02-16 2016-03-31 Vlp Therapeutics Llc Virus like particle composition
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina METHODS AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
JP6734651B2 (ja) 2013-06-03 2020-08-05 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC マラリアワクチン
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP3119801B1 (en) 2014-03-18 2019-07-17 Fraunhofer Gesellschaft zur Förderung der Angewand Distinguishing flavivirus infection using a recombinant mutant envelope protein
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
BR112017014219A2 (pt) 2014-12-31 2018-03-06 The Usa As Represented By The Secretary Dept Of Health And Human Services vacinas à base de nanopartículas multivalentes
WO2016199936A1 (ja) 2015-06-12 2016-12-15 国立大学法人三重大学 ヒトパラインフルエンザ2型ウイルスベクター及びワクチン
WO2016210127A1 (en) 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
CN108601825B (zh) 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 疫苗组合物
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Also Published As

Publication number Publication date
US9249191B2 (en) 2016-02-02
AP2014007864A0 (en) 2014-08-31
JP2018064556A (ja) 2018-04-26
TW201345926A (zh) 2013-11-16
TWI695844B (zh) 2020-06-11
AR092796A1 (es) 2015-05-06
CN113248626A (zh) 2021-08-13
WO2013122262A1 (en) 2013-08-22
MX357202B (es) 2018-06-28
CA2863695C (en) 2023-01-17
KR20140134289A (ko) 2014-11-21
US20160090403A1 (en) 2016-03-31
JP6306518B2 (ja) 2018-04-04
US20130251744A1 (en) 2013-09-26
NZ717682A (en) 2017-10-27
ZA201405694B (en) 2020-05-27
AU2013221187A1 (en) 2014-08-28
AU2013221187B2 (en) 2017-11-30
EP2814847A4 (en) 2015-10-14
US11345726B2 (en) 2022-05-31
RU2705301C2 (ru) 2019-11-06
CA2863695A1 (en) 2013-08-22
EP2814847B1 (en) 2018-04-18
BR112014020052B1 (pt) 2022-06-21
BR112014020052B8 (pt) 2023-04-18
NZ628206A (en) 2016-03-31
AU2013221187B9 (en) 2018-01-04
JP2015508648A (ja) 2015-03-23
SG11201404711WA (en) 2014-09-26
CN104220462A (zh) 2014-12-17
EP2814847A1 (en) 2014-12-24
KR102181258B1 (ko) 2020-11-20
RU2014133527A (ru) 2016-03-10
BR112014020052A2 (pt) 2017-07-04
MX2014009916A (es) 2015-06-02

Similar Documents

Publication Publication Date Title
ZA201405694B (en) Virus like particle composition
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
GB201102237D0 (en) Particle formulation
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
GB201214504D0 (en) Curable compositions comprising composite particles
GB201200707D0 (en) Composition
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
GB201315350D0 (en) Methods and compositions
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201315347D0 (en) Methods and compositions
EP2867303A4 (en) PARTICLES OF THE SILSESQUIOXANE TYPE
EP2878295A4 (en) COMPOSITION
IL280316B (en) Amphiphilic compounds, preparations and their use
IL237542B (en) Amphiphilic compounds, their preparations and uses
GB201300064D0 (en) Microparticle compositions
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
GB201206035D0 (en) Composition
PL2584028T3 (pl) Cząstka
IL237540B (en) Amphiphilic compounds, their preparations and uses
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
GB201208133D0 (en) Composition
IL237538B (en) Amphiphilic compounds, their preparations and uses
EP2837632A4 (en) COMPOUND JK12A AND ITS PREPARATION
HK1208689A1 (zh) 粒度降低方法